Dolsten Mikael 4

What Happened
Mikael Dolsten, a director of Rocket Pharmaceuticals (RCKT), received equity awards on June 18, 2026: 22,862 restricted stock units (RSUs) and a derivative grant in the form of an option/right covering 64,860 shares. Both awards were reported with an acquisition price of $0.00 (standard for compensatory grants), so there was no cash purchase or sale reported.

Key Details

• Transaction date: June 18, 2026; Form 4 filed July 6, 2026 (filed late relative to the typical 2-business-day deadline).
• Reported items:
  • 22,862 RSUs (code A) at $0.00; RSUs convert 1-for-1 to common stock.
  • Option/right for 64,860 shares (reported as a derivative acquisition, code A) at $0.00.
• Vesting/exercise timing (from footnotes): both the RSUs and the option become fully vested/exercisable on June 18, 2027.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No immediate sale or exercise reported; these are grants/awards, not purchases or cashless exercises.

Context
These are compensatory grants to a director (not an exercise or open-market purchase). RSUs convert to common shares when vested; the option gives the right to buy shares once vested/exercisable. Such grants are routine for executive and director compensation and do not by themselves indicate insider buying or selling sentiment. The late filing delays public visibility into the timing of the awards.